BARBARA ANN KARMANOS CANCER INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00003171
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00002907
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00002656
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
KRN5500 in Treating Patients With Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: KRN5500
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00002923
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
Phase 2
Completed
- Conditions
- LymphomaMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00002552
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 280
- Registration Number
- NCT00002547
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Fenretinide in Treating Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00003250
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-04-05
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00014573
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- Procedure: neoadjuvant therapyDietary Supplement: soy isoflavonesOther: Placebo
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00078923
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00004003
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath